Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials

  • J Surg Oncol. 2019 Apr;119(5):642-652. doi: 10.1002/jso.25441.
Shailesh Advani  1  2 ,  Scott Kopetz  2
Affiliations
  • 1. Social Behavioral Research Branch, National Human Genome Research Institute, National Institute of Health, Bethesda, Maryland.
  • 2. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
PMID: 30852840 DOI: 10.1002/jso.25441
Abstract

Metastatic colorectal Cancer (mCRC) continues to show poor outcomes, with many patients exhausting effective standard-of-care therapy. To explore the current landscape of clinical trials for mCRC, we reviewed over 600 clinical trials that are currently ongoing for mCRC patients. Immunotherapeutic agents form approximately 39% (includes monoclonal antibodies, viruses, vaccines, and immunomodulators) of all agents and targeted therapy forms 45% (tyrosine kinase inhibitors, epigenetic modulators, and Others) of all agents being investigated for mCRC.

Keywords
clinical trials; colorectal cancer; immunotherapy; metastatic; targeted therapy.
Products